Massachusetts General Hospital Cancer Center

https://www.massgeneral.org/cancer-center

 

Insights from 2023 Society for Melanoma Research Annual Meeting
Y

2023 SMR Congress Insights: "Time-to-Event Machine Learning Prediction of Metastatic Recurrence From Early Stage Melanoma"

By Insights from 2023 Society for Melanoma Research Annual Meeting FEATURING Yevgeniy Semenov
By Insights from 2023 Society for Melanoma Research Annual Meeting FEATURING Yevgeniy Semenov
50 views
November 24, 2023
Read more about this here:
"Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma"
"Prediction of early-stage melanoma recurrence using clinical and histopathologic features"
0 Comments
Login to view comments. Click here to Login
Videos
11:21
Massachusetts General Hospital Cancer Center

Uveal Melanoma for Community Oncologists

Feat. K. Montazeri
14:06
Insights from 2023 Society for Melanoma Research Annual Meeting

2023 SMR Congress Insights: "Time-to-Event Machine Learning Pre…

Feat. Y. Semenov
18:31
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CAR/BsAb Toxicity in MM - Prevention, Treatment, and Surv…

Feat. N. S. Raje
10:42
Insights from 2023 EHA® Annual Meeting

Updated Data for Ziftomenib in Adults With NPM1-Mutated R/R AML

Feat. A. Fathi
06:25
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Phase 1/2 TRIDENT-1 Trial - Intracranial …

Feat. J. Lin
16:49
Massachusetts General Hospital Cancer Center

ESR1 Mutations in HR+/HER2- mBC and Their Role in Treatment Outcomes

Feat. S. Wander
17:54
Massachusetts General Hospital Cancer Center

Genetic Heterogeneity in Brain Metastases and Implications for Clini…

Feat. P. Brastianos
09:52
Massachusetts General Hospital Cancer Center

Maintenance Therapy in AML: Protecting Remission, Extending Survival…

Feat. A. Brunner
08:20
Massachusetts General Hospital Cancer Center

ESMO 2021 Updates on 1L DKN-01 + Tislelizumab & Chemotherapy in …

Feat. S. Klempner
12:08
Massachusetts General Hospital Cancer Center

Selpercatinib Efficacy & Safety in Patients With RET-Altered Thy…

Feat. L. Wirth
10:05
i3 Health

Emerging Treatment Strategies for Advanced Cholangiocarcinoma: Molec…

Feat. L. Goyal
50:37
Massachusetts General Hospital Cancer Center

Next Steps in FGFRi in Cholangiocarcinoma: FGFR Pathway & Curren…

Feat. L. Goyal
04:27
Massachusetts General Hospital Cancer Center

ASCO 2021 Highlights From GEOMETRY mono-1 Study on Advanced NSCLC: C…

Feat. R. Heist
16:46
Virtual West Oncology Conference

2021 Updates on mTNBC: Do Olaparib/Talazoparib Improve PFS Compared …

Feat. N. Vidula
18:15
CancerGRACE

Targeted Therapy for EGFR+ NSCLC: What Are the Current Options Upon …

Feat. Z. Piotrowska
10:33
GRACE

Targeted Therapy for EGFR+ NSCLC: How Do We Think About Acquired Res…

Feat. Z. Piotrowska
31:44
Massachusetts General Hospital Cancer Center

Tumor Infiltrating Lymphocytes: What Is the Data That Supports the P…

Feat. K. Flaherty
13:52
2020 ASCO Virtual Direct™ Highlights

Targeting Exon 20 Insertions in NSCLC: Anti-Tumor Activity With T-Dx…

Feat. I. Dagogo-Jack
05:44
2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine…

Feat. I. Dagogo-Jack
07:33
2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Does ADAURA Trial Sug…

Feat. I. Dagogo-Jack
07:14
ecancer

2020 ESMO Update on ADCs in mTNBC: Is Sacituzumab Govitecan More Ben…

Feat. A. Bardia
13:34
2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine…

Feat. I. Dagogo-Jack
26:39
Virtual Diversity in Cancer Care

Risk Factors in Lung Cancer: Which Risk Factor Is Predominant? How I…

Feat. I. Dagogo-Jack